| Category: News

Collaboration will leverage University of Eastern Finland’s leading computational molecular simulation technology to identify novel therapeutic approaches and patient selection strategies as part of SpringWorks’ commitment to developing MAPK pathway targeted therapies.

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced a multi-year research collaboration agreement with the University of Eastern Finland to conduct computational biology work comprehensively investigating effector protein dynamics of a variety of KRAS mutations. The objectives of the collaboration will be to better understand the dynamics and biological consequences of KRAS-effector protein interactions with the goal of guiding patient selection strategies and exploring novel residues for future targeted therapy development. The research will be led by Drs. Antti Poso and Tatu Pantsar, from the School of Pharmacy and DrugTech and CANCER Research Communities, who are leaders in computational molecular dynamics simulation and KRAS protein conformations.